(INOD) Innodata - Overview
Sector: TechnologyIndustry: Information Technology Services | Exchange NASDAQ (USA) | Currency USD | Market Cap: 1.423m | Total Return -6.8% in 12m
Stock: Data Preparation, Data Transformation, Medical Data, Content Distribution
Total Rating 60
Risk 96
Buy Signal -2.32
| Risk 5d forecast | |
|---|---|
| Volatility | 84.7% |
| Relative Tail Risk | -18.3% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.29 |
| Alpha | -47.21 |
| Character TTM | |
|---|---|
| Beta | 3.859 |
| Beta Downside | 2.441 |
| Drawdowns 3y | |
|---|---|
| Max DD | 61.84% |
| CAGR/Max DD | 1.03 |
EPS (Earnings per Share)
Revenue
Risks
Technicals:
volatile
Description: INOD Innodata March 03, 2026
Innodata Inc. is a global data engineering company that provides digital transformation services through three operating segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment specializes in the preparation of training data for artificial intelligence, handling tasks such as data annotation, curation, and hygiene to facilitate AI model deployment. This service model is essential to the Data Processing & Outsourced Services sector, where high-quality, structured datasets are a prerequisite for effective machine learning and Large Language Model (LLM) performance.
The Synodex segment utilizes proprietary platforms to convert medical records into usable digital formats, while the Agility segment offers tools for public relations professionals to target media influencers and monitor global news coverage. Headquartered in New Jersey and serving industries ranging from banking to digital retailing, the company addresses the critical enterprise need for data compliance and consolidation. Investors seeking to evaluate Innodatas specific valuation metrics can review the full profile on ValueRay.
Headlines to watch out for
- AI data preparation services drive Digital Data Solutions revenue
- Synodex platform transforms medical records into digital data
- Agility platform provides marketing communications and PR solutions
- Client concentration risk impacts revenue stability
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 32.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.21 > 0.02 and ΔFCF/TA -2.90 > 1.0 |
| NWC/Revenue: 33.72% < 20% (prev 24.34%; Δ 9.38% < -1%) |
| CFO/TA 0.28 > 3% & CFO 46.8m > Net Income 32.2m |
| Net Debt (-77.8m) to EBITDA (47.2m): -1.65 < 3 |
| Current Ratio: 2.68 > 1.5 & < 3 |
| Outstanding Shares: last quarter (35.5m) vs 12m ago 5.48% < -2% |
| Gross Margin: 39.79% > 18% (prev 0.40%; Δ 3.94k% > 0.5%) |
| Asset Turnover: 178.5% > 50% (prev 150.3%; Δ 28.20% > 0%) |
| Interest Coverage Ratio: 71.57 > 6 (EBITDA TTM 47.2m / Interest Expense TTM 577k) |
Altman Z'' 7.10
| A: 0.50 (Total Current Assets 135.4m - Total Current Liabilities 50.5m) / Total Assets 168.6m |
| B: 0.30 (Retained Earnings 51.2m / Total Assets 168.6m) |
| C: 0.29 (EBIT TTM 41.3m / Avg Total Assets 141.0m) |
| D: 0.80 (Book Value of Equity 49.4m / Total Liabilities 61.5m) |
| Altman-Z'' Score: 7.10 = AAA |
Beneish M -2.92
| DSRI: 1.12 (Receivables 46.5m/28.0m, Revenue 251.7m/170.5m) |
| GMI: 0.99 (GM 39.79% / 39.58%) |
| AQI: 0.59 (AQ_t 0.13 / AQ_t-1 0.21) |
| SGI: 1.48 (Revenue 251.7m / 170.5m) |
| TATA: -0.09 (NI 32.2m - CFO 46.8m) / TA 168.6m) |
| Beneish M-Score: -2.92 (Cap -4..+1) = A |
What is the price of INOD shares?
As of March 28, 2026, the stock is trading at USD 37.12 with a total of 2,100,816 shares traded.
Over the past week, the price has changed by -14.98%, over one month by -15.96%, over three months by -28.73% and over the past year by -6.80%.
Over the past week, the price has changed by -14.98%, over one month by -15.96%, over three months by -28.73% and over the past year by -6.80%.
Is INOD a buy, sell or hold?
Innodata has received a consensus analysts rating of 4.60.
Therefore, it is recommended to buy INOD.
- StrongBuy: 3
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the INOD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 91.3 | 145.8% |
| Analysts Target Price | 91.3 | 145.8% |
INOD Fundamental Data Overview March 23, 2026
P/E Trailing = 47.4565
P/E Forward = 55.8659
P/S = 5.6561
P/B = 13.288
P/EG = 0.8726
Revenue TTM = 251.7m USD
EBIT TTM = 41.3m USD
EBITDA TTM = 47.2m USD
Long Term Debt = 4.43m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.20m USD (from shortTermDebt, last quarter)
Debt = 4.43m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -77.8m USD (from netDebt column, last quarter)
Enterprise Value = 1.35b USD (1.42b + Debt 4.43m - CCE 82.2m)
Interest Coverage Ratio = 71.57 (Ebit TTM 41.3m / Interest Expense TTM 577k)
EV/FCF = 37.75x (Enterprise Value 1.35b / FCF TTM 35.6m)
FCF Yield = 2.65% (FCF TTM 35.6m / Enterprise Value 1.35b)
FCF Margin = 14.16% (FCF TTM 35.6m / Revenue TTM 251.7m)
Net Margin = 12.79% (Net Income TTM 32.2m / Revenue TTM 251.7m)
Gross Margin = 39.79% ((Revenue TTM 251.7m - Cost of Revenue TTM 151.5m) / Revenue TTM)
Gross Margin QoQ = 38.34% (prev 41.39%)
Tobins Q-Ratio = 7.98 (Enterprise Value 1.35b / Total Assets 168.6m)
Interest Expense / Debt = 13.02% (Interest Expense 577k / Debt 4.43m)
Taxrate = 22.24% (2.53m / 11.4m)
NOPAT = 32.1m (EBIT 41.3m * (1 - 22.24%))
Current Ratio = 2.68 (Total Current Assets 135.4m / Total Current Liabilities 50.5m)
Debt / Equity = 0.04 (Debt 4.43m / totalStockholderEquity, last quarter 107.1m)
Debt / EBITDA = -1.65 (Net Debt -77.8m / EBITDA 47.2m)
Debt / FCF = -2.18 (Net Debt -77.8m / FCF TTM 35.6m)
Total Stockholder Equity = 91.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 22.82% (Net Income 32.2m / Total Assets 168.6m)
RoE = 35.11% (Net Income TTM 32.2m / Total Stockholder Equity 91.6m)
RoCE = 42.98% (EBIT 41.3m / Capital Employed (Equity 91.6m + L.T.Debt 4.43m))
RoIC = 35.03% (NOPAT 32.1m / Invested Capital 91.7m)
WACC = 19.53% (E(1.42b)/V(1.43b) * Re(19.56%) + D(4.43m)/V(1.43b) * Rd(13.02%) * (1-Tc(0.22)))
Discount Rate = 19.56% (= CAPM, Blume Beta Adj.) -> capped to 17.38%
Shares Correlation 3-Years: 100.0 | Cagr: 5.31%
[DCF] Terminal Value 52.28% ; FCFF base≈32.3m ; Y1≈39.8m ; Y5≈68.0m
[DCF] Fair Price = 12.57 (EV 332.0m - Net Debt -77.8m = Equity 409.8m / Shares 32.6m; r=19.53% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 82.27 | EPS CAGR: 73.31% | SUE: 0.29 | # QB: 0
Revenue Correlation: 93.49 | Revenue CAGR: 38.75% | SUE: 0.52 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.21 | Chg7d=-0.085 | Chg30d=-0.085 | Revisions Net=-1 | Analysts=2
EPS current Year (2026-12-31): EPS=1.20 | Chg7d=-0.085 | Chg30d=-0.085 | Revisions Net=+1 | Growth EPS=+29.9% | Growth Revenue=+35.7%
EPS next Year (2027-12-31): EPS=1.74 | Chg7d=+1.735 | Chg30d=+1.735 | Revisions Net=+0 | Growth EPS=+45.2% | Growth Revenue=+27.0%
[Analyst] Revisions Ratio: -1.00 (0 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 15.3% (Discount Rate 17.4% - Earnings Yield 2.1%)
[Growth] Growth Spread = +21.6% (Analyst 36.9% - Implied 15.3%)
P/E Forward = 55.8659
P/S = 5.6561
P/B = 13.288
P/EG = 0.8726
Revenue TTM = 251.7m USD
EBIT TTM = 41.3m USD
EBITDA TTM = 47.2m USD
Long Term Debt = 4.43m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.20m USD (from shortTermDebt, last quarter)
Debt = 4.43m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -77.8m USD (from netDebt column, last quarter)
Enterprise Value = 1.35b USD (1.42b + Debt 4.43m - CCE 82.2m)
Interest Coverage Ratio = 71.57 (Ebit TTM 41.3m / Interest Expense TTM 577k)
EV/FCF = 37.75x (Enterprise Value 1.35b / FCF TTM 35.6m)
FCF Yield = 2.65% (FCF TTM 35.6m / Enterprise Value 1.35b)
FCF Margin = 14.16% (FCF TTM 35.6m / Revenue TTM 251.7m)
Net Margin = 12.79% (Net Income TTM 32.2m / Revenue TTM 251.7m)
Gross Margin = 39.79% ((Revenue TTM 251.7m - Cost of Revenue TTM 151.5m) / Revenue TTM)
Gross Margin QoQ = 38.34% (prev 41.39%)
Tobins Q-Ratio = 7.98 (Enterprise Value 1.35b / Total Assets 168.6m)
Interest Expense / Debt = 13.02% (Interest Expense 577k / Debt 4.43m)
Taxrate = 22.24% (2.53m / 11.4m)
NOPAT = 32.1m (EBIT 41.3m * (1 - 22.24%))
Current Ratio = 2.68 (Total Current Assets 135.4m / Total Current Liabilities 50.5m)
Debt / Equity = 0.04 (Debt 4.43m / totalStockholderEquity, last quarter 107.1m)
Debt / EBITDA = -1.65 (Net Debt -77.8m / EBITDA 47.2m)
Debt / FCF = -2.18 (Net Debt -77.8m / FCF TTM 35.6m)
Total Stockholder Equity = 91.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 22.82% (Net Income 32.2m / Total Assets 168.6m)
RoE = 35.11% (Net Income TTM 32.2m / Total Stockholder Equity 91.6m)
RoCE = 42.98% (EBIT 41.3m / Capital Employed (Equity 91.6m + L.T.Debt 4.43m))
RoIC = 35.03% (NOPAT 32.1m / Invested Capital 91.7m)
WACC = 19.53% (E(1.42b)/V(1.43b) * Re(19.56%) + D(4.43m)/V(1.43b) * Rd(13.02%) * (1-Tc(0.22)))
Discount Rate = 19.56% (= CAPM, Blume Beta Adj.) -> capped to 17.38%
Shares Correlation 3-Years: 100.0 | Cagr: 5.31%
[DCF] Terminal Value 52.28% ; FCFF base≈32.3m ; Y1≈39.8m ; Y5≈68.0m
[DCF] Fair Price = 12.57 (EV 332.0m - Net Debt -77.8m = Equity 409.8m / Shares 32.6m; r=19.53% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 82.27 | EPS CAGR: 73.31% | SUE: 0.29 | # QB: 0
Revenue Correlation: 93.49 | Revenue CAGR: 38.75% | SUE: 0.52 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.21 | Chg7d=-0.085 | Chg30d=-0.085 | Revisions Net=-1 | Analysts=2
EPS current Year (2026-12-31): EPS=1.20 | Chg7d=-0.085 | Chg30d=-0.085 | Revisions Net=+1 | Growth EPS=+29.9% | Growth Revenue=+35.7%
EPS next Year (2027-12-31): EPS=1.74 | Chg7d=+1.735 | Chg30d=+1.735 | Revisions Net=+0 | Growth EPS=+45.2% | Growth Revenue=+27.0%
[Analyst] Revisions Ratio: -1.00 (0 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 15.3% (Discount Rate 17.4% - Earnings Yield 2.1%)
[Growth] Growth Spread = +21.6% (Analyst 36.9% - Implied 15.3%)